



## Press Release

# **Cipla Announces its Management Council**

- ~ Names a six-member Management Council
- ~ Appoints Umang Vohra as its Global Chief Operating Officer
- ~ Expands role of Samina Vaziralli, Executive Director to include Strategy and M &A

**India, Mumbai, January 7, 2016:** Cipla Limited, a global pharmaceutical company is pleased to announce the creation of a six member Management Council that will be the apex executive leadership team for the company. This is part of its ongoing transformation journey to simplify decision making and improve operational excellence. It also announced the appointment of Umang Vohra, currently the Global Chief Financial and Strategy Officer, as its Global Chief Operating Officer with immediate effect. He replaces Sudhanshu Priyadarshi who has decided to pursue interests beyond Cipla.

The role of the Global Chief Operating Officer has now been expanded to fully integrate end-to-end operations from making, supplying and selling our products, thereby simplifying the organisation. In his new role, Umang Vohra will lead the generics and API businesses across all markets globally. Additionally, he will now integrate technical services, global supply chain, global portfolio, business development & licensing and business planning functions. He will continue with his assignment as the Global Chief Financial Officer of the Company.

Samina Vaziralli, Executive Director, will now be the company's Global Head for strategy, M&A, Cipla New Ventures and key partner relationships.

Headed by Subhanu Saxena, Managing Director & Global Chief Executive Officer, the Management Council will include, in addition to Umang Vohra and Samina Vaziralli, Geena Malhotra (Global Head- Integrated Product Development), Dr Ranjana Pathak (Global Head-Quality) and Prabir Jha (Global Chief People Officer).

Commenting on these developments, Mr Subhanu Saxena, Managing Director and Global Chief Executive Officer said "We are simplifying our leadership structure to prepare Cipla for the next phase of our growth. This is a natural evolution at this stage of our plans."

**Ends**

## **About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

**For further details please contact:**

**Media Contacts:**

**Corporate Communications**

Charlotte Chunawala

Mobile: +91 7506257377

E Mail: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com)

Pallavi Golar

Mobile: +91 9833641788

E Mail: [pallavi.golar@cipla.com](mailto:pallavi.golar@cipla.com)